BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 35028750)

  • 1. Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naïve men: a large cohort validation study.
    Bittencourt LK; Guricova K; Zucker I; Durieux JC; Schoots IG
    Eur Radiol; 2022 Apr; 32(4):2330-2339. PubMed ID: 35028750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of trans-rectal color doppler flow imaging and risk-stratification nomogram reduce unnecessary prostate biopsies in suspected prostate cancer patients: a bi-centered retrospective validation study.
    Guo Y; Su K; Lu M; Liu X
    BMC Urol; 2023 May; 23(1):81. PubMed ID: 37138271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
    Deniffel D; Perlis N; Ghai S; Girgis S; Healy GM; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA
    Eur Radiol; 2022 Nov; 32(11):7544-7554. PubMed ID: 35507051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI/ultrasound fusion prostate biopsy.
    Yusim I; Mazor E; Frumkin E; Jabareen M; Hefer B; Elsaraya N; Li S; Rouvinov K; Novack V; Mabjeesh NJ
    Prostate; 2023 Sep; 83(13):1255-1262. PubMed ID: 37263774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.
    Freifeld Y; Xi Y; Passoni N; Woldu S; Hornberger B; Goldberg K; Bagrodia A; Raj G; Margulis V; Cadeddu JA; Lotan Y; Francis F; Pedrosa I; G Roehrborn C; Costa DN
    Urol Oncol; 2019 Jan; 37(1):57-62. PubMed ID: 30446460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
    Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making.
    Rajendran I; Lee KL; Thavaraja L; Barrett T
    Br J Radiol; 2024 Jan; 97(1153):113-119. PubMed ID: 38263825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Accuracy of MRI-Ultrasound Fusion Targeted Biopsy Based on PI-RADS v2.1 Category in Transition/Peripheral Zone of the Prostate.
    Liu Y; Wang S; Xu G; Zhou B; Zhang Y; Ye B; Xiang L; Zhang Y; Xu H
    J Magn Reson Imaging; 2023 Sep; 58(3):709-717. PubMed ID: 36773016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
    Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
    Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
    Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI-RADS Upgrading Rules: Impact on Prostate Cancer Detection and Biopsy Avoidance of MRI-Directed Diagnostic Pathways.
    de Oliveira Correia ET; Purysko AS; Paranhos BM; Shoag JE; Padhani AR; Bittencourt LK
    AJR Am J Roentgenol; 2024 May; ():1-11. PubMed ID: 38353450
    [No Abstract]   [Full Text] [Related]  

  • 14. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
    Luzzago S; de Cobelli O; Mistretta FA; Piccinelli ML; Lorusso V; Morelli M; Bianchi R; Catellani M; Cozzi G; Di Trapani E; Pricolo P; Alessi S; Ferro M; Marvaso G; Matei DV; Jereczek-Fossa BA; Petralia G; Musi G
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):406-413. PubMed ID: 32989259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
    van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
    Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Magnetic Resonance Imaging-directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis.
    Schoots IG; Padhani AR; Rouvière O; Barentsz JO; Richenberg J
    Eur Urol Oncol; 2020 Feb; 3(1):32-41. PubMed ID: 31706946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.
    Ahdoot M; Lebastchi AH; Long L; Wilbur AR; Gomella PT; Mehralivand S; Daneshvar MA; Yerram NK; O'Connor LP; Wang AZ; Gurram S; Bloom J; Siddiqui MM; Linehan WM; Merino M; Choyke PL; Pinsky P; Parnes H; Shih JH; Turkbey B; Wood BJ; Pinto PA;
    Eur Urol Oncol; 2022 Apr; 5(2):176-186. PubMed ID: 33846112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5].
    Liu Y; Yuan CW; Wu JY; Shen Q; Xiao JX; Zhao Z; Wang XY; Li XS; He ZS; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):812-817. PubMed ID: 37807733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer.
    Stabile A; Dell'Oglio P; Soligo M; De Cobelli F; Gandaglia G; Fossati N; Esposito A; Brembilla G; Karnes RJ; Montorsi F; Briganti A
    Eur Urol Oncol; 2021 Aug; 4(4):594-600. PubMed ID: 31204312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.
    Oderda M; Albisinni S; Benamran D; Calleris G; Ciccariello M; Dematteis A; Diamand R; Descotes JL; Fiard G; Forte V; Giacobbe A; Marquis A; Marra G; Messas A; Muto G; Peltier A; Rius L; Simone G; Roumeguere T; Faletti R; Gontero P
    Prostate; 2023 Feb; 83(2):162-168. PubMed ID: 36259316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.